Scilex Holding Company (SCLX) Fair Value 2026

SCLX · Drug Manufacturers - General ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.2 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (39/100)

Quick Summary — As of 2026-08-27, Scilex Holding Company (SCLX) trades at $5.57. QOC: 5.2/10. Value Trap Risk: 39/100 (LOW). 1/13 models active.

Key Facts

Ticker
SCLX
Price
$5.57
Quality Score
5.2/10
Value Trap Risk
39/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +388.2% upside with 33% confidence
Risk: Limited model coverage (1/13) may reduce confidence

What Fair Value Does Each Model Give SCLX?

1 Intrinsic Value Models vs. Current Price ($5.57)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $27.19 +388.2%

All Models Active

All 1 models are displayed above.

What Is Scilex Holding Company (SCLX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Scilex Holding Company is potentially undervalued at its current price of $5.57. Based on our 13-model framework, Scilex Holding Company's intrinsic value is estimated at a median fair value of $27.19 — representing +388.2% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About SCLX?

1 of 13 models are currently active for SCLX. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does SCLX Rank in Drug Manufacturers - General?

Among 21 Drug Manufacturers - General stocks, SCLX ranks #17 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.

Scilex Holding Company's positioning within the Drug Manufacturers - General segment means that FDA approval probability plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.

Is SCLX a Value Trap?

CirclFi's Value Trap algorithm assigns SCLX a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Scilex Holding Company. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Scilex Holding Company earns a quality score of 5.2/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SCLX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SCLX's 1 active models, average confidence is 33%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Scilex Holding Company Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - General Stocks Should You Also Analyze?

10 related Drug Manufacturers - General stocks with 13-model coverage

AMRNAmarin Corporation plcQOC 6.1MIRAMIRA Pharmaceuticals, Inc.QOC 4.7GRFSGrifols, S.A.QOC 6.9MDCXMedicus Pharma Ltd.QOC 4.0OGNOrganon & Co.QOC 7.3NVSNovartis AGQOC 2.8GILDGilead Sciences, Inc.QOC 9.7JNJJohnson & JohnsonQOC 9.0ABBVAbbVie Inc.QOC 7.6MRKMerck & Co., Inc.QOC 9.6

Read investment analysis: AMRN · MIRA · GRFS · MDCX · OGN · NVS · GILD · JNJ · ABBV · MRK

Which Other Stocks Have a Similar Quality Score to SCLX?

7 companies across all industries closest to SCLX’s Quality of Company score of 5.2/10.

MCIBarings Corporate InvestorsQOC 5.2MREOMereo BioPharma Group plcQOC 5.2PMHSPolomar Health Services, Inc.QOC 5.2RMCFRocky Mountain Chocolate Factory, Inc.QOC 5.2ALDXAldeyra Therapeutics, Inc.QOC 5.2SNDASonida Senior Living, Inc.QOC 5.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MCI · MREO · PMHS · RMCF · ALDX · SNDA · NVDA

What Else Do Investors Ask About Scilex Holding Company’s Valuation?

What is Scilex Holding Company's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Scilex Holding Company (SCLX). The Quality of Company score is 5.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SCLX overvalued or undervalued right now?

At $5.57, 1 of 1 active models suggest SCLX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Scilex Holding Company's business model in Drug Manufacturers - General.

What does a Quality of Company score of 5.2 mean for SCLX?

Scilex Holding Company's QOC of 5.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SCLX?

CirclFi analyzes SCLX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is SCLX a value trap in 2026?

Scilex Holding Company's Value Trap score is 39/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Scilex Holding Company (SCLX) a Quality of Company score of 5.2/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/SCLX/ · Methodology
Primary sources for this SCLX valuation
  • Financial statements: Scilex Holding Company 10-K and 10-Q filings on SEC EDGAR (CIK 0001820190) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SCLX as of ; valuations recomputed .